ZIOPHARM Oncology (ZIOP) Given Daily Media Impact Rating of 0.21
Headlines about ZIOPHARM Oncology (NASDAQ:ZIOP) have trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ZIOPHARM Oncology earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.2481490179134 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several equities research analysts recently weighed in on the stock. ValuEngine cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. BidaskClub upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, HC Wainwright set a $10.00 target price on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $13.17.
ZIOPHARM Oncology (ZIOP) opened at 6.17 on Friday. The firm’s 50-day moving average is $5.85 and its 200-day moving average is $6.25. ZIOPHARM Oncology has a 52 week low of $4.84 and a 52 week high of $7.88. The company’s market cap is $867.70 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. The business’s revenue for the quarter was down 5.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.01) EPS. On average, analysts expect that ZIOPHARM Oncology will post ($0.56) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/24/ziopharm-oncology-ziop-given-daily-media-impact-rating-of-0-21.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.